Trump to sign the most preferred nation’s drug pricing orders

president Donald Trump On Monday, he revived a controversial policy aimed at this Reducing drug costs By linking the prices of some drugs in the United States to these low low abroad.

Trump has signed an executive, including many different measures to renew this effort, known as the “most preferred nation” policy. He did not refer to specific countries, but he indicated that he would target other developed countries because “there are some countries that need some additional help, and this is good.”

“Basically, what we do is a draw,” Trump said during a press event on Monday. “We will pay the lowest price in the world. We will get someone to pay the lowest price, and this is the price we will get.”

White House officials did not reveal the drugs that will be applied to, but they said it would affect the commercial market as well as Medicare and Medicaid. They said that the two announcement would be broader than a similar policy, Trump tried to push during his first term, which only applies to Medicare Part B.

The officials added that the administration will focus in particular on drugs that have “the largest and largest expenses”, which can include popular treatment for weight loss and diabetes called GLP-1.

It is unclear how effective policy is to reduce patients’ costs. In a post on social media on Monday, Trump claimed that drug prices would be reduced by “59 %, in addition to!”

But Trump, during the press event, claimed that drug prices may decrease more, between 59 % and 80 %, or “I think up to 90 %”.

Some Wall Street and other experts also asked whether the policy could be implemented.

On Monday note, JPMorgan analysts called politics a “challenge to implement in practice” because it is likely to require the approval of Congress and can face legal obstacles.

It is Trump’s latest effort to try to curb the prices of prescribed drugs in the United States, which is Two to three times on average of those In other developed countries – up to 10 times more than some countries, according to Rand Corp. , It is a public policy research center.

In a statement on Monday, Perma, the company Perma, in Trump, praised Trump to aim for other countries “not to pay its fair share.”

However, the CEO of PHRMA Stephen Opel said that “importing foreign prices from socialist countries will be a bad deal for American patients and workers” because it will harm the industry’s ability to bring new treatments to them. Some experts said that the matter may face challenges from the drug industry.

Despite the matter, the shares of drug makers in the United States rose on Monday. MerkA share added more than 4 %, while Vizar and Amgen More than 2 % rose

Aarp, who calls for the elderly of the Americans, thanked Trump for issuing the matter in a statement on Monday.

“For a very long time, the major pharmaceutical companies were tearing the elderly in America – which led to the increase in prices in the world for medical prescriptions to save lives, destroy their profits at the expense of America’s life, and forcing the elderly to overcome medicines that they cannot afford,” Nancy Limand said in the statement.

Food and drug administration also directs to think about expanding imports from other developed countries outside Canada. Trump The executive order signed separate In April, the Food and Drug Administration is directed to improve Process Through it, the states can apply to the import of low -cost drugs from Canada, among other procedures aimed at lower prices of drugs.

The Monday also directs the Ministry of Justice Committee and the Federal Trade Committee to enforce “anti -competition measures” strongly in the United States

The Ministry of Trade will also consider export restrictions that “feed and enable this low pricing abroad.”

The industry also pressed against Trump’s similar plans during its first term. Try Pushing In the last months of this term, but a federal judge to stop Voltage After the case From the pharmaceutical industry. Then the Biden administration canceled this policy.

White House officials Initially compressed Politico reported earlier this month that Republicans in the Congress to include providing the most preferred country in the main reconciliation bill they plan to pass in the coming months, but politics would specifically target drug costs for medical aid. Many members of the Republican Party opposed this measure.

The largest commercial group in industry, Perma, estimated Trump’s proposal may cost Midikid pharmaceutical makers up to $ 1 trillion over a decade.

Some health policy experts said that the most preferred drug policy for the nation may not be effective in reducing the costs of the drug.

For example, Usc experts said This policy “cannot be retracted by the basic economy of the global pharmaceutical market”, as 70 % of pharmaceutical profits come around the world from the world from the United States

“In the face of the choice between the deep cuts in their American prices or the weak lifting of foreign markets, we can expect that many companies come out of foreign markets at their closest opportunities,” experts said in a report in April.

They said this would let the Americans pay the same amount for medicines, and drug makers with low profits and future generations of patients with less innovation.

“In short, everyone loses,” experts said.

Even if the pharmaceutical industry declines to Trump’s executive order in the court, his administration still has another tool to reduce drug prices: Medicare’s drug price negotiations.

It is a major provision of the law to reduce inflation that gives Medicare the ability to negotiate some of the prices of medicines prescribed with manufacturers for the first time in history.

Last month, Trump suggested a change in the policy that pharmaceutical makers have long sought. Legionships on both sides of the corridor can be accepted by the idea, which suggests changing the rules that distinguish between small molecular drugs and biological drugs.

Trump said last week that he was planning to announce the customs tariff for drugs that were imported to the United States during the next two weeks. These planned fees aim to enhance the manufacture of local drugs.

Medicines makers, including Eli Lily and VizarThey pay these possible duties. Some companies wondered whether the definitions were necessary, given that many of them are already New investments for manufacturing, research and development have announced in the United States Since Trump took office.

However, Trump last week doubled the efforts to re -manufacture drugs. An executive thing reduces the path of drug makers to build new production sites.